The Patent Finder

Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)

Amgen Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 14 of these applications claim priority to application 61/086,133, filed Aug 4, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,168,762Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · High confidence
Amgen Inc.In force
High confidence
US 8,829,165Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 8,859,741Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · High confidence
Amgen Inc.In force
High confidence
US 8,871,913Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 8,871,914Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 8,883,983Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 8,889,834Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 8,981,064Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 9,056,915Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
US 9,493,576Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
In force
 · Medium confidence
Amgen Inc.In force
Medium confidence
18 more patents in this group · Pro
10 of 28 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 28.
Upgrade to Pro
14 of these are in force and held by Amgen Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited